News

Genta Announces Webcast of 2008 Annual Shareholders Meeting

BERKELEY HEIGHTS, N.J.-(Business Wire)-October 2, 2008 - Genta Incorporated (OTCBB: GNTA) announced that the Company will host a conference call and live audio webcast of its 2008 Annual Meeting of Shareholders. The meeting will be held on Monday, October 6, 2008 at 11:00 a.m., EDT at the Company’s headquarters located at 200 Connell Drive, Berkeley Heights, NJ 07922. The presentation will include an overview of the Company's key programs and strategies by senior management.

Conference call and webcast information:

US/Canada call: 877-634-8606; conference code Genta Annual Shareholder Meeting

International call: 706-679-3140; conference code Genta Annual Shareholder Meeting

Audio Webcast: http://www.genta.com/genta/InvestorRelation/events.html.

Audio replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S./Canada) and (706) 645-9291 (International); conference ID number is: 64394129. Shareholders wishing to attend the meeting may obtain directions by visiting the Genta website at www.genta.com.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

SAFE HARBOR

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:

the Company’s ability to obtain necessary regulatory approval for Genasense^® from the U.S. Food and Drug Administration (“FDA”) or European Medicines Agency (“EMEA”);
the safety and efficacy of the Company’s products or product candidates;
the Company’s assessment of its clinical trials;
the commencement and completion of clinical trials;
the Company’s ability to develop, manufacture, license and sell its products or product candidates;
the Company’s ability to enter into and successfully execute license and collaborative agreements, if any;
the adequacy of the Company’s capital resources and cash flow projections, the Company’s ability to obtain sufficient financing to maintain the Company’s planned operations, or the Company’s risk of bankruptcy if it is unsuccessful in obtaining such financing or in securing shareholder approval to increase the number of shares authorized for issuance under the Company’s certificate of incorporation, as required by the transactional documents in our recent financing;
the adequacy of the Company’s patents and proprietary rights;
the impact of litigation that has been brought against the Company and its officers and directors and any proposed settlement of such litigation; and
the other risks described under Certain Risks and Uncertainties Related to the Company’s Business, as contained in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

Send this news item to a friend.

Print This Page